Glycosylated SV2A and SV2B Mediate the Entry of Botulinum Neurotoxin E into Neurons

被引:185
作者
Dong, Min [1 ,2 ]
Liu, Huisheng [1 ,2 ]
Tepp, William H. [3 ]
Johnson, Eric A. [3 ]
Janz, Roger [4 ,5 ]
Chapman, Edwin R. [1 ,2 ]
机构
[1] Univ Wisconsin, Howard Hughes Med Inst, Madison, WI 53706 USA
[2] Univ Wisconsin, Dept Physiol, Madison, WI 53706 USA
[3] Univ Wisconsin, Dept Food Microbiol & Toxicol, Madison, WI 53706 USA
[4] Univ Texas Houston, Sch Med, WM Keck Ctr Learning & Memory, Houston, TX 77030 USA
[5] Univ Texas Houston, Sch Med, Dept Neurobiol & Anat, Houston, TX 77030 USA
基金
美国国家卫生研究院;
关键词
D O I
10.1091/mbc.E08-07-0765
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Botulinum neurotoxin E (BoNT/E) can cause paralysis in humans and animals by blocking neurotransmitter release from presynaptic nerve terminals. How this toxin targets and enters neurons is not known. Here we identified two isoforms of the synaptic vesicle protein SV2, SV2A and SV2B, as the protein receptors for BoNT/E. BoNT/E failed to enter neurons cultured from SV2A/B knockout mice; entry was restored by expressing SV2A or SV2B, but not SV2C. Mice lacking SV2B displayed reduced sensitivity to BoNT/E. The fourth luminal domain of SV2A or SV2B alone, expressed in chimeric receptors by replacing the extracellular domain of the low-density lipoprotein receptor, can restore the binding and entry of BoNT/E into neurons lacking SV2A/B. Furthermore, we found disruption of a N-glycosylation site (N573Q) within the fourth luminal domain of SV2A rendered the mutant unable to mediate the entry of BoNT/E and also reduced the entry of BoNT/A. Finally, we demonstrate that BoNT/E failed to bind and enter ganglioside-deficient neurons; entry was rescued by loading exogenous gangliosides into neuronal membranes. Together, the data reported here demonstrate that glycosylated SV2A and SV2B act in conjunction with gangliosides to mediate the entry of BoNT/E into neurons.
引用
收藏
页码:5226 / 5237
页数:12
相关论文
共 60 条
  • [1] Botulinum toxin: A successful therapeutic protein
    Aoki, KR
    [J]. CURRENT MEDICINAL CHEMISTRY, 2004, 11 (23) : 3085 - 3092
  • [2] Botulinum toxin as a biological weapon - Medical and public health management
    Arnon, SS
    Schechter, R
    Inglesby, TV
    Henderson, DA
    Bartlett, JG
    Ascher, MS
    Eitzen, E
    Fine, AD
    Hauer, J
    Layton, M
    Lillibridge, S
    Osterholm, MT
    O'Toole, T
    Parker, G
    Perl, TM
    Russell, PK
    Swerdlow, DL
    Tonat, K
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (08): : 1059 - 1070
  • [3] SV2, A BRAIN SYNAPTIC VESICLE PROTEIN HOMOLOGOUS TO BACTERIAL TRANSPORTERS
    BAJJALIEH, SM
    PETERSON, K
    SHINGHAL, R
    SCHELLER, RH
    [J]. SCIENCE, 1992, 257 (5074) : 1271 - 1273
  • [4] BRAIN CONTAINS 2 FORMS OF SYNAPTIC VESICLE PROTEIN-2
    BAJJALIEH, SM
    PETERSON, K
    LINIAL, M
    SCHELLER, RH
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (06) : 2150 - 2154
  • [5] DIFFERENTIAL EXPRESSION OF SYNAPTIC VESICLE PROTEIN-2 (SV2) ISOFORMS
    BAJJALIEH, SM
    FRANTZ, GD
    WEIMANN, JM
    MCCONNELL, SK
    SCHELLER, RH
    [J]. JOURNAL OF NEUROSCIENCE, 1994, 14 (09) : 5223 - 5235
  • [6] Association of botulinum neurotoxin serotypes A and B with synaptic vesicle protein complexes
    Baldwin, Michael R.
    Barbieri, Joseph T.
    [J]. BIOCHEMISTRY, 2007, 46 (11) : 3200 - 3210
  • [7] BOTULINUM NEUROTOXIN-A SELECTIVELY CLEAVES THE SYNAPTIC PROTEIN SNAP-25
    BLASI, J
    CHAPMAN, ER
    LINK, E
    BINZ, T
    YAMASAKI, S
    DECAMILLI, P
    SUDHOF, TC
    NIEMANN, H
    JAHN, R
    [J]. NATURE, 1993, 365 (6442) : 160 - 163
  • [8] BLASI J, 1993, EMBO J, V12, P4821, DOI 10.1002/j.1460-2075.1993.tb06171.x
  • [9] BUCKLEY K, 1985, J CELL BIOL, V100, P1284, DOI 10.1083/jcb.100.4.1284
  • [10] Bullens RWM, 2002, J NEUROSCI, V22, P6876